CD22 CAR T-cell therapy was tested in 34 relapsed or refractory pediatric and adult B-ALL patients, who were unsuccessful with previous rounds of CD19 CAR T cell therapy [51]. The gene discussed is CD22; the disease is precursor B-cell acute lymphoblastic leukemia.